- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00713635
Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome
The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Congenital heart disease (CHD) is the most common class of birth defect and is a major cause of infant and child death and morbidity, including neurodevelopmental delay. Children with severe forms of CHD are at high risk for a spectrum of neurocognitive difficulties that include learning disability, attention deficit and hyperactivity disorder, behavioral problems and mental retardation. The etiology of neurodevelopmental delay in children with CHD is not fully understood but is thought to be secondary to a combination of pre- and post-natal insults to the brain. It has been observed that fetuses with severe forms of CHD have abnormal blood flow to the brain as measured by Doppler ultrasound. This "centralization" or redirection of blood flow toward vital organs such as the brain has been shown to lead to abnormal brain development in other fetal diseases, such as intrauterine growth restriction. Evidence of the importance of prenatal brain development in the setting of CHD is amounting. Neonates with complex CHD demonstrate abnormalities of brain structure and blood flow prior to cardiothoracic surgery. However, to date, associations between abnormal fetal brain blood flow and neonatal neurologic outcomes and brain function have not been established in the CHD population. Finally, newborns with CHD have been shown to have abnormalities in heart rate over a 24 hour period. This finding suggests that the autonomic nervous system, which controls heart rate and blood pressure, may not function properly in infants with CHD.
The study proposes that these changes in blood flows in the fetus with heart disease could be responsible in part for poor brain growth, abnormal brain structure and function and developmental delay in childhood. Investigators will use routine obstetrical ultrasound and fetal echocardiograms to evaluate blood flow to vital organs and brain growth in fetuses with CHD. Investigators will use non-invasive fetal monitors to measure fetal heart rate and movement. Investigators will look at brain structure using Magnetic Resonance Imaging (MRI) in the fetus and newborn. Afterbirth, investigators will use non-invasive monitors to measure neonatal heart rate and blood pressure changes in response to a tilt, similar to what is experienced when placing an infant in a car seat. Investigators will use a non-invasive monitor consisting of a sticker applied to the skin to measure the level of oxygen in the brain. Investigators will also measure brain function in the newborn with an electroencephalogram(EEG) that records the electrical signaling between different parts of the brain using a special plastic hat like a swim cap. Regular physical exams with a pediatrician to measure growth and development will take place. A special test designed to detect learning disabilities will also be done when the child is 14 months old. This test will consist of talking with the child, reading stories, and showing the child pictures and colors. There will be no extra blood tests needed and none of the tests pose any risk to the mother, fetus, infant, or child.
The possible benefits to the child and the family will be early identification of any brain abnormality in the newborn period as well as learning disabilities in the toddler which will then allow the child to receive therapies designed to treat these problems. Studies show that early identification and treatment of learning disabilities are important to enhance the potential of the child.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10032
- Columbia University College of Physicians & Surgeons, Morgan Stanley Children's Hospital of New York
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- All women who present to Columbia University Medical Center between 18-24 wks gestational age with the following fetal diagnoses will be invited to participate:
- Hypoplastic Left Heart Syndrome (HLHS)
- Transposition of the Great Arteries (TGA)
- Tetralogy of Fallot (TOF)
- Lung anomalies consisting of either congenital cystic adenomatoid malformations or bronchogenic cysts
Exclusion Criteria:
- Documented fetal chromosomal anomaly
- Structural brain malformations
- Evidence of placental insufficiency or Intrauterine growth retardation
- Documented hydrops fetalis or sustained cardiac arrhythmias
- Anticipated delivery at an outside hospital
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
1
Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
|
|
2
Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
|
|
3
Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
|
|
4
Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Neurodevelopmental scores as measured by the Bayley Scales of Infant Development
Délai: 18 months of age
|
18 months of age
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG
Délai: Neonatal EEG within 72 hours of birth
|
Neonatal EEG within 72 hours of birth
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Délai: Fetal assessment between 18-24 wk GA
|
Fetal assessment between 18-24 wk GA
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Délai: Fetal assessment between 28-32 wk GA
|
Fetal assessment between 28-32 wk GA
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Délai: Fetal assessment between 34-38 wk GA
|
Fetal assessment between 34-38 wk GA
|
|
Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG
Délai: Neonatal EEG at 1 month of age
|
Neonatal EEG at 1 month of age
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Ismee A Williams, MD, MS, Columbia University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AAAD1879
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .